BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

REGENX Biosciences, LLC 

750 17th St. NW, Suite 1100

Washington  D.C.   20006  U.S.A.
Phone: 202-785-7438 Fax:


SEARCH JOBS








 Company News
REGENX Biosciences, LLC And AveXis Enter Into Exclusive License Agreement For The Development Of Treatments For Spinal Muscular Atrophy Using NAV® rAAV9 Vectors 4/1/2014 11:09:56 AM    More...
REGENX Biosciences, LLC And Esteve S.A. (Laboratorios Del Dr. Esteve S.A.) Enter Into License Agreement For Development Of Treatments For Serious, Rare Lysosomal Storage Disorder Using NAV® rAAV9 Vectors 3/10/2014 10:12:48 AM    More...
Dr. James Brown, COO, REGENX Biosciences, LLC, Elected To SAFE-BioPharma, LLC Board Of Directors 2/11/2014 10:08:08 AM    More...
REGENX Biosciences, LLC And LYSOGENE Enter Into Exclusive License Agreement For Development Of Treatments For Serious, Rare Lysosomal Storage Disorder Using NAV(R) rAAVrh10 Vectors 12/5/2013 9:45:32 AM    More...
Fidelity Biosciences and REGENX Biosciences, LLC Form New Company Dimension Therapeutics 10/31/2013 12:19:59 PM    More...
REGENX Biosciences, LLC and Audentes Therapeutics Enter into Exclusive License Agreement for Development of Treatments for Serious, Rare Muscle Diseases Using NAVTM Vectors 7/30/2013 10:06:57 AM    More...
REGENX Biosciences, LLC and Audentes Therapeutics Enter Into Exclusive License Agreement for Development of Treatments for Serious, Rare Muscle Diseases Using NAV™ Vectors 7/30/2013 9:10:51 AM    More...
REGENX Biosciences, LLC Consortium Awarded $7.7 Million Grant From EC for the Advancement of Clinical Development Program Using NAV™ rAAV8 Vectors 3/27/2013 10:27:27 AM    More...
REGENX Biosciences, LLC Receives FDA Orphan Designation for Treatment of Familial Hypercholesterolemia Using NAV(TM) rAAV8 Vectors 4/10/2012 8:51:08 AM    More...
REGENX Biosciences, LLC and Asklepios BioPharmaceutical, Inc. Enter Into Agreement for the Development of Treatments for Hemophilia A Using NAV(TM) rAAV8 Vectors 3/8/2012 8:49:39 AM    More...

//-->